File an Investigational Drug Application for a Phase 1 study of UNI-494
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 14 Nov 2022
- Due
- 31 Mar 2023
- Checked
- 1 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Unicycive plans to file an Investigational Drug Application (IND) with the FDA in early 2023”
What we found
Evidence strength A What the grades mean
The company did not file an IND for a Phase 1 study of UNI-494 in early 2023, instead shifting its FDA IND filing plans to 2024 for a Phase 2 trial.
-
A Unicycive Therapeutics, Inc. 8-K filed 2023-03-31
“plans to file a corresponding Investigational New Drug (IND) application with the FDA in 2024 for a Phase 2 proof-of-concept trial” ✓ confirmed on the page
Market reaction: the shares moved +14.7% against the S&P 500 over the three sessions around the disclosure (30 Mar 2023 to 4 Apr 2023). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +641 days
- 2 versions
-
Version 1 · original · stated 14 Nov 2022
Deadline 31 Mar 2023 (“in early 2023”) · wording expected
-
Version 2 · stated 31 Mar 2023
Deadline 31 Dec 2024 (“2024”) · wording expected
“plans to file a corresponding Investigational New Drug (IND) application with the FDA in 2024”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory filing
- Indicative materiality
- Medium rules
- Action
- File
- Deliverable
- UNI-494 Investigational Drug Application
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Unicycive Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-UNCY-002779 · Corrections policy